Research ArticleTranslational
Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein
Thomas Lindner, Anastasia Loktev, Annette Altmann, Frederik Giesel, Clemens Kratochwil, Jürgen Debus, Dirk Jäger, Walter Mier and Uwe Haberkorn
Journal of Nuclear Medicine September 2018, 59 (9) 1415-1422; DOI: https://doi.org/10.2967/jnumed.118.210443
Thomas Lindner
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Anastasia Loktev
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
2Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany
3Faculty of Biosciences, Heidelberg University, Heidelberg, Germany
Annette Altmann
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
2Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany
Frederik Giesel
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Clemens Kratochwil
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Jürgen Debus
4Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
5Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; and
Dirk Jäger
6Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany
Walter Mier
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Uwe Haberkorn
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
2Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 59, Issue 9
September 1, 2018
Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein
Thomas Lindner, Anastasia Loktev, Annette Altmann, Frederik Giesel, Clemens Kratochwil, Jürgen Debus, Dirk Jäger, Walter Mier, Uwe Haberkorn
Journal of Nuclear Medicine Sep 2018, 59 (9) 1415-1422; DOI: 10.2967/jnumed.118.210443
Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein
Thomas Lindner, Anastasia Loktev, Annette Altmann, Frederik Giesel, Clemens Kratochwil, Jürgen Debus, Dirk Jäger, Walter Mier, Uwe Haberkorn
Journal of Nuclear Medicine Sep 2018, 59 (9) 1415-1422; DOI: 10.2967/jnumed.118.210443
Jump to section
Related Articles
Cited By...
- Diagnostic Potential of Supplemental Static and Dynamic 68Ga-FAPI-46 PET for Primary 18F-FDG-Negative Pulmonary Lesions
- 68Ga-FAPI PET/CT as an Alternative to 18F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma
- Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies
- Imaging of Tumor Stroma Using 68Ga-FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial
- Immunohistochemical FAP Expression Reflects 68Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma
- Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-{alpha} (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors
- Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein {alpha}
- 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial
- Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers
- Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib
- [68Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis
- PET imaging of fibroblast activation protein alpha (FAP) detects incipient cardiotoxicity due to anthracycline chemotherapy
- Performance of 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Evaluation of Erdheim-Chester Disease: A Comparison with 18F-FDG PET/CT
- Tumor Characterization by [68Ga]FAPI-46 PET/CT Can Improve Treatment Selection for Pancreatic Cancer Patients: An Interim Analysis of a Prospective Clinical Trial
- [68Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis
- Fibroblast Activation Protein Inhibitor-Based Radionuclide Therapies: Current Status and Future Directions
- First Total-Body Kinetic Modeling and Parametric Imaging of Dynamic 68Ga-FAPI-04 PET in Pancreatic and Gastric Cancer
- Radiolabeled GPVI-Fc for PET Imaging of Multiple Extracellular Matrix Fibers: A New Look into Pulmonary Fibrosis Progression
- 68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study
- Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities
- Clinical Translation of Targeted {alpha}-Therapy: An Evolution or a Revolution?
- Fibroblast Activation Protein-Targeted Radioligand Therapy for Treatment of Solid Tumors
- Clinical Translation of Targeted {alpha}-Therapy: An Evolution or a Revolution?
- Static and Dynamic 68Ga-FAPI PET/CT for the Detection of Malignant Transformation of Intraductal Papillary Mucinous Neoplasia of the Pancreas
- Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging
- Head-to-Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT for Evaluation of Head and Neck Squamous Cell Carcinoma: A Single-Center Exploratory Study
- FAPI PET Opens a New Window to Understanding Immune-Mediated Inflammatory Diseases
- Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
- The Added Value of 68Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with 18F-FDG-Negative Findings
- Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of 68Ga-Labeled FAPI Dimer
- Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients
- Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results
- Detecting Fibroblast Activation Proteins in Lymphoma Using 68Ga-FAPI PET/CT
- Perspective on Fibroblast Activation Protein-Specific PET/CT in Fibrotic Interstitial Lung Diseases: Imaging Fibrosis--A New Paradigm for Molecular Imaging?
- 68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational Trial
- Fibroblast Activation Protein-Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study
- The Annual Journal Impact Factor Saga
- Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?
- Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas
- An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications
- FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?
- FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
- The Latest Developments in Imaging of Fibroblast Activation Protein
- Fibroblast Activation Protein-Targeted PET/CT with 68Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18F-FDG PET/CT
- {alpha}v{beta}6-Targeted Molecular PET/CT Imaging of the Lungs After SARS-CoV-2 Infection
- Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor
- Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging
- Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy
- Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography
- The Role of 68Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience
- Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
- Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models
- FAP: The Next Billion Dollar Nuclear Theranostics Target?
- Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04
- A Conversation Between Uwe Haberkorn and Johannes Czernin
- Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention
- The Future of Nuclear Medicine as an Independent Specialty
- Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
- Novel Structured Reporting Systems for Theranostic Radiotracers
- 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers